Format

Send to

Choose Destination
Med Sci (Paris). 2019 Dec;35(12):975-981. doi: 10.1051/medsci/2019241. Epub 2020 Jan 6.

[Which immunoglobulin heavy chains for which immunostimulatory antibodies?]

[Article in French; Abstract available in French from the publisher]

Author information

1
Équipe Fc receptors, antibodies and microenvironment, EA7501 GICC, Université de Tours, Tours, France.
2
Équipe Fc receptors, antibodies and microenvironment, EA7501 GICC, Université de Tours, Tours, France - Laboratoire d'immunologie, CHU de Tours, Tours, France.

Abstract

in English, French

Immunostimulatory antibodies in cancer rely on different mechanisms of action, simple blocking of immune checkpoints, depletion of tumour-infiltrating regulatory T cells, agonistic action on lymphocyte activatory receptors, etc. Choosing the relevant heavy chain isotype or the adequate engineering variant of this heavy chain is critical for the therapeutic efficacy, since the aforementioned properties sometimes bring into play the Fc region and the hinge region. This short review tries to learn the lessons from the clinical experience.

PMID:
31903902
DOI:
10.1051/medsci/2019241

Supplemental Content

Full text links

Icon for EDP Sciences
Loading ...
Support Center